
AAVACC ANNOUNCES KEY MILESTONE TOWARDS PED VACCINE REGISTRATION

Singapore, 18th September 2018 – AAVACC announced today that its lead vaccine candidate, AVC-P118V, achieved a major milestone in its path towards regulatory approval.

AVC-P118V is a vaccine against the porcine epidemic diarrhoea (“**PED**”) virus, it is administered to pregnant sows and provides protection to them and their new-born piglets¹. The vaccine is based on Artificial Cell Membrane (“**ACM**”) technology which comprises antigens incorporated in polymeric vesicles (“**polymersomes**”) that elicit a strong antigen-specific immune response.

Dr. Thomas Cornell, a Senior Scientist in AAVACC, stated: *“The United States Department of Agriculture’s Center for Veterinary Biologics recently issued a letter stating that the safety data submitted to them regarding our novel polymers and polymersomes are acceptable to allow the use of our polymersome technology for our AVC-P118V vaccine for food animals. This is an extremely important milestone for us, and we are now able to move towards pivotal trials of AVC-P118V confident that our base polymeric materials will not cause safety concerns later in the licensing process.”*

About AAVACC Pte Ltd

AAVACC Pte Ltd is a subsidiary of ACM Biolabs Pte Ltd and is focused on the development and commercialization of ACM-based veterinary vaccines. ACM Biolabs is a synthetic biology company using its proprietary Artificial Cell Membrane (“ACM”) technology platform to develop novel vaccines. AAVACC has licensed technology from ACM Biolabs, the Agency for Science, Technology and Research (A*STAR), Singapore’s lead public sector agency for science, research and development, and from Nanyang Technological University (NTU) a research-intensive University in Singapore which is consistently ranked among the world’s best Universities.

Media Contact: info@AAVACC.com

¹ The AVC-P118V vaccine follows from the sow / piglet trials announced previously, see: <https://www.acmbiolabs.com/content/acmbiolabs/docs/20161004-ACM-BIOLABS-Press-Release-PED-2nd-animal-trials.pdf>